Feedzy Demo Page – Knight Therapeutics

Mandalay Resources rapporterar stabil produktion under andra kvartalet, 101 miljoner USD i likvida medel och avgörande investeringar för att stödja tillväxten vid Costerfield

TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) tillkännager andra kvartalets produktionsresultat för kvartalet som slutade den 30 juni 2025.
Revival Gold Announces Strategic Placement with EMR Capital and C$24 Million Capital Raise

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA.
AlphaGen Announces Closing of Debt Settlement Transaction

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AlphaGen Intelligence Corp. (CSE: AIC | OTC: APETF | FSE: W4V) (“AlphaGen'' or the “Company”) announces, further to its news release dated July 3, 2025, that it has issued 2,251,326 common shares in the capital of the Company (each, a “Share”), at a deemed price of $0.1463 per Share in settlement of outstanding debts owed to certain creditors of the Company, including Eli Dusenbury (a director and the CFO of the Company) in the amount of $329,369.58 (the “Debt Settlement”).
South Bow Announces Timing of Second-quarter 2025 Results and Conference Call and Webcast

CALGARY, Alberta, July 10, 2025 (GLOBE NEWSWIRE) -- South Bow Corp. (TSX & NYSE: SOBO) (South Bow or the Company) will release its second-quarter 2025 financial and operational results after the close of markets on Aug. 6, 2025.
Seeley Holdings Ltd. News Release

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Seeley Holdings Ltd. (the “Company”) announces that the Company has entered into an agreement with Pasinex Resources Limited (the “Issuer”) to convert an aggregate principal amount of $1,116,636.85 of debt (the “Settlement Amount”) owing by the Issuer to the Company into common shares of the Issuer (the “Common Shares”) on a non-brokered private placement basis pursuant to the accredited investor exemption in section 2.3 of National Instrument 45-106 - Prospectus and Registration Exemptions (the “Debt Settlement Transaction”). The Company will acquire ownership and control of 14,888,491 Common Shares (the “Settlement Shares”) in exchange for the settlement of the Settlement Amount at a price of $0.075 per Settlement Share.